BACKGROUND
B cells play a central role in the pathogenesis of systemic lupus erythematosus (SLE) and are a therapeutic target. We therefore assessed the efficacy and safety of obinutuzumab β, a glycoengineered type II anti-CD20 monoclonal antibody, in patients with active SLE.
METHODS
In this multicentre, randomised,...
Yu-Hui Li, Gui-Xiu Shi, Guo-Ping Jiang et al.· The Lancet Rheumatology· 0 citations
Although CD20-directed B cell depletion has long been used in neuromyelitis optica spectrum disorder (NMOSD), high-quality, large-scale, randomized controlled trials remain limited. In this multicenter, randomized, double-blind phase 3 trial, we evaluated obinutuzumab β (MIL62), a novel glycoengineered type II anti-CD2...
Lei Wu, Liangliang Gu, Wei-Hao Fan et al.· Nature Medicine· 1 citation
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.